Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 E Medical Center Drive
Ann Arbor, MI 48109Phone+1 734-764-3066- Is this information wrong?
Summary
- Dr. David Smith is an oncologist in Ann Arbor, MI and is affiliated with the University of Michigan Medical Center and Michigan Medicine. He received his medical degree from University of Washington School of Medicine and has been in practice 32 years. He specializes in genitourinary oncology and is experienced in clinical trials, prostate and bladder cancer, and testicular neoplasms.
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
- University of WashingtonResidency, Internal Medicine, 1985 - 1988
- University of Washington School of MedicineClass of 1985
Certifications & Licensure
- MI State Medical License 1995 - 2024
- PA State Medical License 1992 - 1996
- NC State Medical License 1990 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor.Allison J Schepers, David C Smith, Rachel L McDevitt> ;Journal of Oncology Pharmacy Practice. 2023 Jun 1
- 2 citationsFirst-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.James J Harding, Christiane Jungels, Jean-Pascal Machiels, David C Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K Abou...> ;Targeted Oncology. 2023 Mar 1
- 1 citationsSurvival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, Joh...> ;Journal of Clinical Oncology. 2023 Feb 10
- Join now to see all
Journal Articles
- Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer ImmunotherapyDavid Smith, Sarah Yentz, Biodrugs
Professional Memberships
- Member
- Member
Hospital Affiliations
- University of Michigan Medical CenterAnn Arbor, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: